Tsubame BHB was established in April of 2017 based on a new catalyst technology developed by Prof. em. Hideo Hosono at the Tokyo Institute of Technology (Tokyo Tech), which allows an ammonia process at lower temperature and pressure.
American football is a fascinating sport that is gaining more and more fans in Germany and elsewhere.
Affix Labs over the past 5 years has specialized in binding technologies and commercialized first products in 2019.
Hafnium Labs is tackling one of the toughest challenges in chemical R&D: Obtaining reliable physical property data — fast.
In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.
Online Monitoring and Control of Bioreactors by Mid-Infrared Spectroscopy
Single-step, Ambient, Dry Grafting of Organic Compounds and Biomolecules onto any Substrate.
Hybrid assemblies, joints of dissimilar materials, are everywhere - in our smartphones, cars, TVs, dishwashers, in planes and so on. However, in modern products we increasingly rely on plastics, which are intrinsically hard to bond to other types of material — and by using industrial glue for the bonding the parts cannot be recycled easily. Solving this monumental challenge inspired the foundation of the Danish start-up company RadiSurf five years ago.
Molecule.one leverages artificial intelligence (AI) to design novel chemical syntheses. As a response to the outbreak of the Covid-19 pandemic, the Polish start-up based in Warsaw has set out on the mission to accelerate the process of creating medicines.
Iris.ai was founded at Singularity University at NASA Ames Research Park in 2015. Challenged to come up with an idea that would positively impact the lives of 1 billion people, the team was formed and problem areas were explored.
New therapies to address unmet and emerging medical needs are being discovered at an explosive rate, building on rapid advances in molecular biology and genetics.
Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs.
Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs. Indeed, medicinal chemists face a challenge of their own. Trying to survive in a changing environment where pharma is focusing on biologics drug candidates will require chemists to adapt.
